DECLARATION FOR PATENT APPLICATION

AS A BELOW-NAMED INVENTORS, WE HEREBY DECLARE THAT:

Our residence, post office address, and citizenship are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled: **PEPTIDE YY AND PEPTIDE YY AGONISTS FOR TREATMENT OF METABOLIC DISORDERS**, the specification of which is attached hereto unless the following box is checked:

was filed on as U	United States Application Serial No.	or PCT
International Applicat	ion No. and was amended on	(if applicable).

WE HEREBY STATE THAT WE HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION.

We acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

We hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
			□Yes □No

We hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Application Serial No.	Filing Date	,
60/256.216	Dec. 15, 2000	

We hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, we acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status			
		□Patented	□Pending	□Abandoned	

We hereby appoint the following attorneys and agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Molly A. Holman (Reg. No. 40,022) Joanna Moore (Reg. No. 44,950)

Please direct all communications to:

Molly A. Holman, Ph.D. Amylin Pharmaceuticals, Inc. 9373 Towne Centre Drive San Diego, California 92009

Please direct all telephone calls to Molly A. Holman at (858) 552-2200, facsimile (858) 552-1936 and e-mail mholman@amylin.com.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

17/14/01

Date

Name: Residence: Citizenship: Richard A. Pittner 805 22nd Street, San Diego, California 92102

British

Post Office Address:

805 22nd Street, San Diego, California 92102

12/14/01 Date

Name: Residence:

Citizenship:
Post Office Address:

Andrew A. Young

5679 La Jolla Hermosa Ave., La Jolla, California 92037

New Zealand

5679 La Jolla Hermosa Ave., La Jolla, California 92037

12/14/01 Date

Name: Residence:

Citizenship:
Post Office Address:

James R. Paterniti, Jr.

10833 Birch Bluff Avenue, San Diego, California 9213

United States

10833 Birch Bluff Avenue, San Diego, California 92131